• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Palmaz Scientific co-founders, board sued by bankruptcy trustee

Palmaz Scientific co-founders, board sued by bankruptcy trustee

March 7, 2017 By Brad Perriello

Palmaz ScientificA trustee in the bankruptcy proceedings for Palmaz Scientific Inc. last week sued its co-founders and members of its board, alleging that they looted the company before declaring bankruptcy last year.

Co-founded by coronary stent pioneer Dr. Julio Palmaz and CEO Steven Solomon in 2008 to commercialize Palmaz’s ideas, PSI raised about $40 million before pulling the plug in a year ago.

The company told its shareholders in August 2015 that Palmaz planned to resign as chairman in favor of former Kinetic Concepts Inc. CEO Cathy Burzik; serving as interim CEO, Burzik was to have helped find a replacement for Solomon and land a cash infusion backed by Targeted Technology, where she is an operating partner. Palmaz was to have remained as chief scientific officer. But the deal fell apart within days after Targeted Technology backed out. Palmaz told MassDevice.com at the time that the decision to end the deal was mutual and in the best interest of Palmaz Scientific’s shareholders. He has not since responded to requests for comment.

PSI blamed its problems on a Texas investment banker, Susan Harriman, claiming that its “ability to attract capital investment and continue its business operations has been seriously impaired by a negative campaign of false information.” Harriman allegedly lied about the company to “investors, potential business partners, the news media and even federal government authorities – resulting in substantial damage to the company and crippling its ability to maintain its ongoing operations.” But a lawsuit filed by PSI against Harriman in the U.S. District Court for Western Texas was dismissed without prejudice in 2015.

The picture painted by a new lawsuit is very different. Filed March 3 in Dallas County District Court by Milo Segner Jr., the liquidating trustee charged with recovering any legal claims, the suit alleges that Palmaz and Solomon “sold out the corporate enterprise.”

“The company was managed on a day to day basis almost exclusively by Solomon and Palmaz. Indeed, Solomon and Palmaz operated through an executive committee of the board of directors, which appears to be have been impermissibly authorized and certainly did not follow form or practice consistent with PSI’s bylaws,” Segner wrote. “Based on the official corporate minutes, it does not appear that any actions by the executive committee were ever reported to the full board of directors or communicated to the full board of directors.”

In fact, Segner alleged, PSI did not hold a single board meeting for 6 years, until the problems at the company were to big to conceal. Solomon was paid more than $3.4 million over the course of the company’s life, Segner claimed, while Palmaz walked away with the intellectual property that was PSI’s most valuable asset.

“Solomon and Palmaz also authorized for themselves extensive stock grants, which had the effect of enlarging their personal stock holdings and diluting other investors. No disinterested board of directors approved the compensation and at the time the compensation was paid and the stock was granted, PSI was massively insolvent and relying entirely upon private investor monies to fund operations,” the trustee wrote.

The company posted an operating loss of -$5.4 million in 2012, with debts of some $30 million. The numbers were worse the next year, even though PSI put up revenues of $759,000 from a supply contract – the net loss bloomed to -$9.4 million and the accumulated debt mounted to $38.9 million.

“The actions of Solomon and Palmaz are particularly egregious considering PSI’s financial position,” Segner wrote. “Remarkably, after blowing through nearly $40 million of investor funds, PSI had no products or clear path to commercialization to show for the losses, despite promising investors for years that such was on the horizon.”

Segner’s lawsuit also alleges that Palmaz, Solomon and board members Phillip Romano, Christopher Banas, Eugene Sprague and John Asel failed to ensure that crucial evidence in the bankruptcy was preserved, despite being aware that the company was likely headed to court as early as the spring of 2014.

“Defendants Palmaz, Solomon, Sprague, Romano and Asel were certainly on notice no later than August of 2015 to preserve any and all evidence related to false statements contained in investor solicitation materials. Despite the awareness of questioning investors, claims to inspect the corporate books and records, and specific evidence preservation letters, it appears that no safeguards were put in place to protect and preserve the integrity of either hard-copy documentary evidence or electronic evidence,” Segner wrote.

Segner also accused Solomon of taking computers home in late July 2015, wiping their memories and returning them to the factory default settings before returning them to the company.

“No forensic copy or mirror image of those computers was created or maintained by PSI’s directors and officers,” he wrote. “In addition, electronic mail and other electronic data from PSI appears to have been deleted from the relevant time period and not preserved or imaged, despite a general and specific awareness of potential or threatened litigation.

“Defendants’ actions constitute either intentional or negligent breaching of a duty or obligation to preserve evidence. Defendants appear to have taken no action whatsoever to preserve evidence, much less exercise reasonable care in preserving and maintaining evidence relevant and material to investor inquiries and threats. 126. The Trustee demands a jury instruction regarding spoliation of evidence in his favor,” Segner wrote.

Filed Under: Legal News, Stents Tagged With: Bankruptcy, Palmaz Scientific

In case you missed it

  • ResMed expects steady growth over the next year
  • Ambu is letting go of 200 employees
  • Medtronic has Class I recall for low-shock risk in ICDs
  • Titan Medical to start manufacturing Enos systems later this year
  • ZimVie sales down more than 11% in Q2 as it streamlines after spinoff
  • Cardinal Health’s CFO to move up to corner office
  • Levita Magnetics raises $26M for Magnetic-Assisted Robotic Surgery platform
  • Data supports use of Channel Medsystems Cerene cryotherapy
  • The 10 largest orthopedic device companies in the world
  • Nanopath raises $10M Series A for women’s health diagnostics
  • Avenda wins FDA IDE nod for AI-enabled prostate cancer therapy
  • NuVasive chief commercial officer Massimo Calafiore is stepping down
  • Preparing your medical device company for challenging market conditions
  • Dentsply Sirona replaces chief accounting officer amid internal investigation
  • Haemonetics stock rises on Street-beating Q1, raised guidance
  • Surgalign settles on OEM business sale, posts Q2 earnings miss
  • Alcon lowers its 2022 forecast amid strong dollar

RSS From Medical Design & Outsourcing

  • FDA’s breakthrough medical device designations tally nears 700
    Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted almost 700 designations over the past seven years under a voluntary program for expedited regulatory review of medical devices and combination products that facilitate more effective treatment or diagnosis of serious diseases. According to recent metrics published by FDA, the agency has issued a total of… […]
  • Lifecore Biomedical’s owner plans to go all-in on contract development and manufacturing
    Lifecore Biomedical parent company Landec Corp. (Nasdaq:LNDC) plans to take the subsidiary’s name, leadership and headquarters as its own and sell off food businesses to focus on contract development and manufacturing. Santa Maria, California-based Landec said it will rename itself as Lifecore Biomedical “in the near future” and change its Nasdaq ticker to LFCR. Landec… […]
  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]
  • GE Healthcare picks AI imaging startups for inaugural Edison Accelerator
    GE Healthcare and Nex Cubed have selected seven companies focused on artificial-intelligence-augmented medical imaging for the first cohort of the Edison Accelerator in Canada. The companies will be matched with mentors and test their technologies with GE’s new Edison Digital Health Platform over the next three months. The program will end with innovation showcase presentations… […]
  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]
  • Blue Spark’s TempTraq catches fevers faster. Fever prediction is next.
    Blue Spark Technologies developed the first wireless continuous temperature monitor patch, TempTraq, to enable faster fever detection than standard manual readings every four hours. Westlake, Ohio-based Blue Spark is now looking at fever prediction rather than just detecting them. The R&D team is working on developing an AI neural network model built on the company’s… […]
  • Harvard researchers plan to sell at-home, PCR-grade COVID testing system
    The Harvard University researchers who developed an ultrasensitive, PCR-grade nucleic acid detection technology plan to commercialize it as a portable COVID-19 test. Harvard Medical School professor Peng Yin, who also leads the Wyss Institute for Biologically Inspired Engineering’s Molecular Robotics Initiative, founded 3EO Health to sell the device. “In order to optimize the value of… […]
  • FDA reports sterilization challenge progress as EPA takes aim at EtO emissions
    The FDA offered an update on its efforts to make medical device sterilization safer as the EPA identified 23 U.S. facilities where use of ethylene oxide (EtO) presents a risk to communities. The FDA said it is similarly concerned about unsafe EtO emissions and highlighted work with the medical device industry to reduce EtO usage… […]

Primary Sidebar

DeviceTalks Weekly

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy